Joyce Cheng
6PUBLICATIONS
66CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.Melanie Royce, Mirat Shah, Lijun Zhang
|Jun 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.Sandra J Casak, Vaibhav Kumar, Chi Song
|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.Michael J Fusco, Sandra J Casak, Sirisha L Mushti
|Sep 07, 2023
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.Timil H Patel, Jamie R Brewer, Jiaxin Fan
|Jun 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.Sandra J Casak, M Naomi Horiba, Mengdie Yuan
|Jun 08, 2023
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.Shruti U Gandhy, Sandra J Casak, Sirisha L Mushti
Pageof 1
Frequent Collaborators
6 joint publications
Richard Pazdur
6 joint publications
Paul G Kluetz
5 joint publications
Steven J Lemery
5 joint publications
Lola A Fashoyin-Aje
4 joint publications
Sandra J Casak
4 joint publications
Doris Auth
3 joint publications
Shenghui Tang
3 joint publications
Youwei Bi
2 joint publications
Sirisha L Mushti
2 joint publications
Hong Zhao
